Advanced Esophageal Cancer Clinical Trial
Official title:
PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial
This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of SHR-1210 + paclitaxel + cisplatin vs placebo+paclitaxel +cisplatin as 1L therapy for advanced esophageal cancer patients in China. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
In this study, eligible subjects will be randomized into study arm or control arm. Treatment cycles of chemotherapy will be at most 6 cycles which would be decided by the investigators. Progression-free survival (PFS) assessed by the Independent Review Committee (IRC) and overall survival (OS) will be the primary outcomes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03706326 -
CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05425472 -
A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer
|
Phase 2 | |
| Recruiting |
NCT05174156 -
Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer
|
Phase 2 |